

The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma. New Jersey-based Slayback is focused on generic and specialty pharmaceutical products.
Source: Press Release
The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma.
The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma. New Jersey-based Slayback is focused on generic and specialty pharmaceutical products.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination